Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IWWM-11 2022 | Long non-coding RNA expression in IgM-MGUS and Waldenström’s macroglobulinemia

Jonas Paludo • 28 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia

Jonas Paludo, MD, Mayo Clinic, Rochester, MN, shares some insights into the importance of long non-coding RNA expression in Waldenström’s macroglobulinemia (WM), and how the expression of these RNAs may play a role in disease progression. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Karyopharm and Biofourmis – both research funding to my institution

More from Jonas Paludo

Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy 2:36
Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy
Jonas Paludo • 28 Oct 2022
The importance of studying RNA expression in rare diseases such as WM 0:57
The importance of studying RNA expression in rare diseases such as WM
Jonas Paludo • 28 Oct 2022
0:56
Waldenström’s macroglobulinemia highlights from ASH 2018
Jonas Paludo • 4 Dec 2018
2:15
Association between depth of response and survival in Waldenström’s
Jonas Paludo • 6 Dec 2018

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals